![Oncotarget](https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png)
Improved Efficacy of Pembrolizumab When Combined With sEphB4-HSA in HPV-negative EphrinB2-positive HNSCC
July 22, 2024
Future development for sEphB4-HSA in HNSCC is likely to focus on patients with HPV-negative disease where there is greatest need to improve on the outcomes with pembrolizumab monotherapy.”BUFFALO, NY-... read more